Lymphatic Education
& Research Network

Other Grants & Awards Programs

• Complex Lymphatic Anomalies Young Investigator Award

  The Orphan Disease Center Complex Lymphatic Anomalies (CLA) Young Investigator award is a one-year grant designed to support early career researchers, such as postdoctoral and clinical fellows or instructors, pursuing promising research ideas related to lymphatic anomalies including Gorham Stout Disease (GSD), Generalized Lymphatic Anomaly (GLA), Kaposiform Lymphangiomatosis (KLA) and Central Conducting Lymphatic Anomaly (CCLA). These grants aim to cultivate the best and brightest researchers of the future who demonstrate a commitment to a career in lymphatic research. This is a mentored award, and the proposed research project will be conducted by the awardee under the guidance of a scientific mentor.  Proposals in all areas of lymphatic research are welcome from U.S. and international applicants. 

  The YIA is a one-year award totaling $25,000 that supports personnel and/or direct research expenses.  Up to two awards are available. These awards are made possible by the Lymphangiomatosis & Gorham’s Disease Alliance (LGDA and LGDA Europe) and the Lymphatic Malformation Institute (LMI).

  This RFA is open globally. International applicants are invited to apply. Applicants must have a PhD, MD, or MD/PhD or equivalent and must not have achieved an appointment higher than Instructor.

  Review the Request for Applications for submitting an LOI.  The one-page LOI is due no later than Friday, June 3, 2022 by 8pm (EST).

  To submit an LOI or for more information, click here.

  Learn More >
• The Snyder Research Grant

  The Snyder Research Grant from the Foundation of Physical Therapy Research (FPTR) supports clinical research projects in the area of physical therapy. Especially:

  ·    Services delivered by physical therapists.
  ·    Developments of new interventions that offer reasonable assurance that they will be clinically relevant and therapeutically effective.
  The applicant must work at a U.S. institution and already have a PhD or will have a PhD by October 15. The Grant is intended for emerging investigators who have not yet received substantial federal funding for their research. The maximum funding amount is 40,000 USD during a 1 to 2 years grant period. Indirect or overhead costs are not included. Applications close on August 5, 2022.

  Learn More >
• The Paris Patla Physical Therapy Research Grant

  The Paris Patla Physical Therapy Research Grant from the Foundation of Physical Therapy Research (FPTR) supports research projects that evaluate the effectiveness of interventions most commonly delivered by physical therapists as determined by current practice standards and developing innovative physical therapist interventions and evaluating their effectiveness. Priority is given to projects that evaluate not only therapeutic effectiveness but also cost effectiveness. The applicant must work at a U.S. institution and the recipient must be US citizens or permanent residents. The funding amount is 100,000 USD. Overhead costs are not included. This is an annual grant – the letters of Intent are due on June 1, 2022, and the invited full applications are due on August 5, 2022.

  Learn More >
• Request for Applications: Two Patient-Partnered RFAs with Rare Disease Focus

  Applications due May 24, 2022 by 5 p.m. Pacific Time

  The Chan Zuckerberg Initiative (CZI) invites applications from collaborative teams bringing together patient-led rare disease organizations and research teams for 4-year research projects aimed at advancing our understanding of the fundamental science of rare diseases across two RFAs:

  - The Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease RFA aims to support the application of single-cell biology methods to rare inflammatory pediatric diseases in order to clarify cellular mechanisms of disease, improve understanding of disease heterogeneity, identify biomarkers, and improve diagnosis.

  The overarching goal is to support interdisciplinary teams as they characterize the cellular mechanisms underlying rare inflammatory diseases, including possible identification of biomarkers and elucidation of disease pathways that will clarify disease stratification or identify therapeutic opportunities. Patient organizations are expected to be active collaborators on this research opportunity and full partners in the development of the grant application to directly inform research questions that will have the greatest impact on rare disease patients, and to engage in study design, patient engagement, and research dissemination. Learn more and apply now.

  - The Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA aims to advance the understanding of the pathophysiology and mechanistic underpinnings of rare neurodegenerative and neurological disorders.

  CZI’s Neurodegeneration Challenge Network model is built on the vision that progress in solving neurodegenerative diseases will come from bringing new people into the neurodegeneration field from diverse disciplines and expertise; building interdisciplinary collaborations; empowering the broader scientific community with robust tools and platforms, and creating a culture of open science. The Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA extends on this vision by expanding the scope of diseases and biological problems covered within NDCN, and widens the circle of experts and stakeholders to include patient organizations as collaborators, building on learnings from CZI’s Rare as One Network and CZI’s efforts in patient-directed research. Learn more and apply now.

  We are accepting applications until 5 p.m. Pacific Time on May 24, 2022.

  Questions? Email sciencegrants@chanzuckerberg.com.

  Learn More >
• 2022 AVF-JOBST Clinical Research Grant

  The AVF Foundation is now accepting submissions for the 2022 AVF-JOBST Clinical Research Grant which will provide a $85,000 grant over two years for original, clinical research in venous diseases, lymphatic diseases, or lipedema with an emphasis on:

  - Prevention of disease and its progression
  - Diagnosis of disease
  - The science of management of the above conditions, especially with compression therapy

  This opportunity is open to:

  - Residents and fellows in a training program located in the United States
  - Physicians who have completed their training within the past ten (10) years,have not previously received this award and are currently based in the United States

  Either the applicant or their mentor must be an AVF Member at the time of submission. The awardee is expected to join the AVF and maintain their membership for the duration of the grant period.

  The Application Deadline for the 2022 grant is 5 PM CT on Friday, October 8, 2021.

  For more information regarding eligibility and the application process or to submit an application, click here.

  Learn More >
• Patient-Centered Outcomes Research Institute

  PCORI funds research into conditions that affect large numbers of people across a range of populations; conditions that place a heavy burden on individuals, families, specific populations, and society; and rare diseases, which are difficult to study. PCORI funds research through organizations and not individuals.
  

  PCORI funds research that offers patients and caregivers the information they need to make important healthcare decisions. Our scientific research portfolio is divided among two programs, which together reflect our National Priorities for Research. Each program leads the development of PCORI Funding Announcements that may be either broad calls for applications or targeted to specific topics. These programs also participate in the selection of awards and oversee the projects as they progress.

  In addition, the Evaluation and Analysis program provides evaluation expertise, while the Engagement program gives patients, caregivers, clinicians, and other healthcare stakeholders opportunities for meaningful involvement in all our activities.

  Learn More >
• DOD’s Congressionally Directed Medical Research Programs (CDMRP) - BCRP Pre-Announcements

  Last year researchers looking at the intersection of lymphedema and breast cancer were encouraged to compete for funding opportunities through the CDMRP’s Breast Cancer Research Program (BCRP). Please see the information below in this regard.

  The Fiscal Year 2019 (FY19) Defense Appropriation Act provides funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP). Recently released pre-announcements may be found at http://cdmrp.army.mil/pubs/press/press to allow investigators time to plan and develop ideas for submission to the anticipated FY19 funding opportunities.
  
  FY19 funding opportunities are anticipated to be released in January 2019 for the following programs:
  
  Breast Cancer Research Program
  Ovarian Cancer Research Program
  
  Descriptions of each of the anticipated funding opportunities, eligibility, key mechanism elements, and funding can be found in the respective Program pre-announcement.  FY19 pre-announcements can be found in the CDMRP home page features at http://cdmrp.army.mil.
  
  Researchers investigating the intersection of lymphedema and breast cancer may be interested in the following grant opportunities recently released.
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Innovator Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312196
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Fellowship Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312197
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Level 4 Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312198
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Era of Hope Scholar Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312195
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Distinguished Investigator Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312176

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Levels 1 and 2
  Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312177

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  DoD Breast Cancer, Breakthrough Award Level 3 Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312178

  Learn More >
• DOD’s Congressionally Directed Medical Research Programs (CDMRP) - PRMRP Grant Opportunities

  Peer Reviewed Medical Research Program (PRMRP) Grant Opportunities. – PRMRP funds medical research for a list of conditions and diseases that have been identified by Congress as disproportionately affecting military personnel. LE&RN will be working over the course of this year to include “lymphatic diseases” to this list.
  
  This year’s PRMRP includes “burn pit exposures” and “vascular malformations.” Any researchers looking at this connection between burn pit exposures and the onset of lymphedema should look at the opportunities below. Researchers who are working on research involving vascular or lymphatic malformations may also find funding through these opportunities. Researchers are also encouraged to apply for funding through the designation of vascular malformations as this may encompass vascular anomalies of only veins, only lymph vessels, both veins and lymph vessels, or both arteries and veins.
  (https://www.hopkinsmedicine.org/interventional-radiology/conditions/malformations/index.html)

  LE&RN is working to include “lymphatic diseases” as eligible for study through the fiscal year (FY) 2020 PRMRP and this will definitely improve the ability of researchers to compete successfully for this funding, but the categories above should be seen as an opportunity for researchers to get their foot in the PRMRP’s door.
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Investigator-Initiated Research Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312036
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Technology/Therapeutic Development Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312037
  

  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Discovery Award
  Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312033
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Clinical Trial Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312034
  
  DOD
  Department of Defense
  Dept. of the Army—USAMRAA
  CDMRP PRMRP Focused Program Award Synopsis 1
  https://www.grants.gov/web/grants/view-opportunity.html?oppId=312035

  Learn More >
• 
  Lymphatic researchers needed for NIH Study Sections

  NIH has requested that LE&RN assemble and deliver to NIH a list of lymphatic researchers who are willing to serve on NIH Study Sections. They have identified the following three Study Sections that review lymphatic grant proposals:

  * Hypertension and Microcirculation (HM) Study Section reviews applications dealing with propulsion of lymph, lymphatic tone, and pathogenesis of lymphedema with more focus on functional studies; sometimes reviews applications about the lymphatic system in infection and inflammation depending on the outcome of research, namely whether focused on lymphatics or infection.
  
  
  * Immunity and Host Defense (IHD) and Innate Immunity and Inflammation (III) Study Sections may review applications that address lymphatic role in infection.
  
  
  * Cardiovascular Differentiation and Development (CDD) Study Section reviews applications involving lymphatic development, lymphangiogenesis, and lymphedema focusing on structure.

  If you are willing to serve on one or more of the above-identified NIH Study Sections, please contact LE&RN at LERN@LymphaticNetwork.org with the following information:

  * Name
  * Affiliation
  * Study Section(s) on which you are willing to serve
  * In 50 words or less, your qualifications for each Study Section selected
  * Include CV

  Investigators will not be able to review their own research or research on which they are collaborators. However, this will not prevent your research from being reviewed by the Study Section. Per NIH: If a researcher is on a Study Section and has an application, his or her application is reviewed by a special emphasis panel. This is a common practice that happens all the time. This should not be an obstacle to joining a Study Section.

• Online Partnership to Accelerate Research

  OnPAR (Online Partnership to Accelerate Research) is a matchmaking platform where applicants and non-government funders come together.  Leidos Health’s Life Sciences has partnered with NIH and other funding organizations to accelerate the biomedical research and development enterprise by matching high-scoring unfunded applications with private biomedical foundations and/or industries seeking to fund promising research via OnPAR (e.g., for NIH these would be applications within the 30th percentile but are beyond the funding cutoff).

  OnPAR has member organizations and matches the unfunded applications with the funding organization.  For more information, please visit https://onpar.leidosweb.com/.

  Learn More >